Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Surgery
Published in: BMC Surgery 1/2022

Open Access 01-12-2022 | Metastasis | Research

Hyperthermic intraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: a single Chinese center analysis

Authors: Yunzi Wu, Xiaohao Zheng, Chunyang Sun, Shenghui Wang, Shikang Ding, Ming Wu, Jing Zhang, Bingzhi Wang, Liyan Xue, Lin Yang, Yantao Tian, Yibin Xie

Published in: BMC Surgery | Issue 1/2022

Login to get access

Abstract

Purpose

About 15%—40% of gastric cancer patients have peritoneal metastasis, which leads to poor prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) is considered to be an effective treatment for these patients. This study evaluated the efficacy and safety of HIPEC in patients with gastric cancer diagnosed from laboratory tests.

Methods

The clinical and pathological data of 63 patients with gastric cancer who underwent HIPEC in 2017–2021 were prospectively recorded. Fifty-five patients underwent cytoreductive surgery + HIPEC, and eight patients received HIPEC alone. The factors associated with HIPEC safety and efficacy were analyzed. The primary endpoint was overall survival.

Results

The average patient age was 54.84 years and 68.3% of patients were male. Moreover, 79.4% of patients had a peritoneal carcinoma index (PCI) score of ≤ 7 and 61.9% had a completeness of cytoreduction score of 0. Because of peritoneal metastasis, 29 patients (46.03%) were classified as stage IV. Laboratory tests showed no differences in pre-HIPEC blood test results compared to post-HIPEC results after removing the effects of surgery. HIPEC treatment did not cause obvious liver or kidney damage. Serum calcium levels decreased significantly after HIPEC (P = 0.0018). The Karnofsky performance status (KPS) score correlated with the patient’s physical function and improved after HIPEC (P = 0.0045). In coagulation tests, FDP (P < 0.0001) and D-dimer (P < 0.0001) levels increased significantly and CA242 (P = 0.0159), CA724 (P < 0.0001), and CEA (P < 0.0014) levels decreased significantly after HIPEC. Completeness of cytoreduction score was an independent prognostic factor. HIPEC did not show a survival benefit in patients with gastric cancer (P = 0.5505).

Conclusion

HIPEC is a safe treatment for patients with gastric cancer with peritoneal metastasis based on the laboratory tests. However, the efficacy of this treatment on gastric-derived peritoneal metastases requires further confirmation.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2021;71(3):209–49.CrossRef
2.
Wang S, Zheng R, Zhang S, Zeng H, Chen R, Sun K, Gu X, Wei W, He J. Epidemiological characteristics of gastric cancer in China, 2015. Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(12):1517–21.PubMed
3.
Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):1–23.CrossRef
4.
Lemoine L, Sugarbaker P, Van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperth. 2017;33(5):582–92.CrossRef
5.
6.
Manzanedo I, Pereira F, Rihuete Caro C, Pérez-Viejo E, Serrano Á, Gutierrez Calvo A, Regueira FM, Casado-Adam Á, Cascales-Campos PA, Arteaga X. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol. 2019;26(8):2615–21.CrossRef
7.
Marano L, Marrelli D, Sammartino P, Biacchi D, Graziosi L, Marino E, Coccolini F, Fugazzola P, Valle M, Federici O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with synchronous peritoneal metastases: multicenter study of ‘Italian Peritoneal Surface Malignancies Oncoteam—SICO.’ Ann Surg Oncol. 2021;28(13):9060–70.CrossRef
8.
Yang X-J, Huang C-Q, Suo T, Mei L-J, Yang G-L, Cheng F-L, Zhou Y-F, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.CrossRef
9.
Diniz TP, da Costa Jr WL, Fonseca de Jesus VH, Ribeiro HS, Diniz AL, de Godoy AL, de Farias IC, Torres SM, Felismino TC, Coimbra FJF: Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity‐score matched analysis. J Surg Oncol 2020, 121(5):823–832
10.
Reutovich MY, Krasko O, Sukonko O. Hyperthermic intraperitoneal chemotherapy in serosa-invasive gastric cancer patients. Eur J Surg Oncol. 2019;45(12):2405–11.CrossRef
11.
Zhong Y, Zhang J, Bai X, Sun Y, Liu H, Ma S, Li Y, Kang W, Ma F, Li W. Lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy for advanced gastric cancer: safety and efficacy profiles. Cancer Management and Research. 2020;12:5141.CrossRef
12.
13.
Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Tumori J. 2001;87(4):3–5.CrossRef
14.
Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 2021;41(8):747–95.CrossRef
15.
Smyth E, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38–49.CrossRef
16.
Jamel S, Markar SR, Malietzis G, Acharya A, Athanasiou T, Hanna GB. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer. 2018;21(1):10–8.CrossRef
17.
Bekhor E, Carr J, Hofstedt M, Sullivan B, Solomon D, Leigh N, Bolton N, Golas B, Sarpel U, Labow D. The safety of iterative cytoreductive surgery and HIPEC for peritoneal carcinomatosis: a high volume center prospectively maintained database analysis. Ann Surg Oncol. 2020;27(5):1448–55.CrossRef
18.
Kaaij R, Wassenaar E, Koemans W, Sikorska K, Grootscholten C, Los M, Huitema A, Schellens J, Veenhof A, Hartemink K. Treatment of PERItoneal disease in stomach cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results. J Br Surg. 2020;107(11):1520–8.CrossRef
19.
Mielko J, Rawicz-Pruszyński K, Skórzewska M, Ciseł B, Pikuła A, Kwietniewska M, Gęca K, Sędłak K, Kurylcio A, Polkowski WP. Conversion surgery with HIPEC for peritoneal oli-gometastatic gastric cancer. Cancers. 2019;11(11):1715.CrossRef
20.
Horvath P, Yurttas C, Beckert S, Königsrainer A, Königsrainer I. Twelve-year single center experience shows safe implementation of developed peritoneal surface malignancy treatment protocols for gastrointestinal and gynecological primary tumors. Cancers. 2021;13(10):2471.CrossRef
21.
Lei Z, Wang J, Li Z, Li B, Luo J, Wang X, Wang J, Ba M, Tang H, He Q. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: a multicenter propensity score-matched cohort study. Chin J Cancer Res. 2020;32(6):794.CrossRef
22.
Yan K, Wu K, Yan L, Liang L, Yuan Y. Efficacy of postoperative intraperitoneal hyperthermic perfusion chemotherapy with oxaliplatin+ 5-Fluorouracil in the treatment of gastric cancer patients with peritoneal carcinomatosis. J BUON. 2019;24(4):1587–94.PubMed
23.
Blum Murphy M, Ikoma N, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Song S, Mansfield P, Ajani J. Phase I trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and associated carcinomatosis or positive cytology. Ann Surg Oncol. 2020;27(8):2806–11.CrossRef
24.
Paredes AZ, Guzman-Pruneda FA, Abdel-Misih S, Hays J, Dillhoff ME, Pawlik TM, Cloyd JM. Perioperative morbidity of gastrectomy during CRS-HIPEC: an ACS-NSQIP analysis. J Surg Res. 2019;241:31–9.CrossRef
25.
Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B. Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: a multi-institutional cohort from PSOGI. Eur J Surg Oncol. 2021;47(1):172–80.CrossRef
26.
White MG, Kothari A, Ikoma N, Murphy MB, Song S, Ajani J, Mansfield P, Badgwell B. Factors associated with resection and survival after laparoscopic HIPEC for peritoneal gastric cancer metastasis. Ann Surg Oncol. 2020;27(13):4963–9.CrossRef
27.
Ji Z-H, Yu Y, Liu G, Zhang Y-B, An S-L, Li B, Li X-B, Yan G-J, Li Y. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: a single-center retrospective analysis of 125 patients. Eur J Surg Oncol. 2021;47(6):1411–9.CrossRef
28.
Canbay E, Torun BC, Cosarcan K, Altunal C, Gurbuz B, Bilgic C, Sezgin C, Kaban KK, Yilmaz S, Yazici Z. Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer. J Gastrointest Oncol. 2021;12(Suppl 1):S47.CrossRef
29.
Yarema R, Mielko J, Fetsych T, Ohorchak M, Skorzewska M, Rawicz-Pruszyński K, Mashukov A, Maksimovsky V, Jastrzębski T, Polkowski W. Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: a retrospective cooperative Central-Eastern European study. Cancer Med. 2019;8(6):2877–85.CrossRef
30.
Caro CR, Manzanedo I, Pereira F, Carrion-Alvarez L, Serrano Á, Pérez-Viejo E. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol. 2018;44(11):1805–10.CrossRef
31.
Yonemura Y, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Noguchi K, Takao N, Ichinose M, Liu Y, Li Y. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24(2):478–85.CrossRef
Metadata
Title
Hyperthermic intraperitoneal chemotherapy for patients with gastric cancer based on laboratory tests is safe: a single Chinese center analysis
Authors
Yunzi Wu
Xiaohao Zheng
Chunyang Sun
Shenghui Wang
Shikang Ding
Ming Wu
Jing Zhang
Bingzhi Wang
Liyan Xue
Lin Yang
Yantao Tian
Yibin Xie
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Surgery / Issue 1/2022
Electronic ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-022-01795-6

Other articles of this Issue 1/2022

BMC Surgery 1/2022 Go to the issue

Research

Surgically managed symptomatic intraspinal lumbar facet synovial cyst outcome of surgical treatment with resection and instrumented posterolateral fusion, a case series

Research

Perioperative pectoral nerve block type II and postoperative recurrence in breast cancer: a randomized controlled trial

Research article

When giants talk; robotic dialog during thoracolumbar and sacral surgery

Research

Management of intra-thoracic anastomotic leakages after esophagectomy: updated systematic review and meta-analysis of endoscopic vacuum therapy versus stenting

Research

Posterior atlantoaxial internal fixation using Harms technique assisted by 3D-based navigation robot for treatment of atlantoaxial instability

Case report

Sequential endoscopic and robot-assisted surgical solutions for a rare fungal spondylodiscitis, secondary lumbar spinal stenosis, and subsequent discal pseudocyst causing acute cauda equina syndrome: a case report